SA’s biggest pharmaceutical manufacturer Aspen Pharmacare is on the hunt for acquisitions to help it grow its business in emerging markets, after slashing its debt with a series of disposals that concluded this week with Mylan’s acquisition of the commercial rights to its European thrombosis business for €641.9m .
Aspen CEO Stephen Saad said the company was seeking “bolt-on” rather than transformative acquisitions, and would be looking to buy products to add to its portfolios in the territories it already operated in, which include SA, China, Latin America and Australia.A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.
Loans Loans Latest News, Loans Loans Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Aspen sells European thrombosis business to MylanThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen holds on to dividend over coronavirus uncertaintyThe drugs maker slashed its debt by more than a third over an 18-month period
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen sells European thrombosis business to MylanThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen holds on to dividend over coronavirus uncertaintyThe drugs maker slashed its debt by more than a third over an 18-month period
Source: BDliveSA - 🏆 12. / 63 Read more »